- Email: [email protected]
Patents Alert
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
Comparative Immunology, Microbiology & Infectious Diseases 26 (2003) 285±288
PII: S 0147-957 1(02) 00069-3
285
www.elsevier.com/locate/cimid
286
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
6403094 CLOSTRIDIUM PERFRINGENS VACCINES The present invention provides proteins for use in vaccines which are capable of inducing protective antibodies directed against C. perfringens epsilon toxin when administered to animals or man and thereby providing prophylaxis or therapy against infection by C. perfringens epsilon toxin. Particularly the present invention provides proteins which are based upon the mature toxin of the clostridium perfringensepsilon toxin gene, but which have a mutation such that the amino acid at position 106 is different to the wild-type sequence and their use in vaccine compositions. Richard W. Titball, Ethel D. Williamson, Helen L. Havard, Petra C.F. Oyston, Dean W. Payne, Great Britain assigned to The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland. 6403097
addition to vaccines and a method of treatment. Franciscus Antonius Maria Rijsewijk, Johannes Theodorus van Oirschot, The Netherlands assigned to Stichting Centraal Diergeneeskundig Instituut 6403101 CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, speci®cally C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modi®cations are possible within the scope of this invention. Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn, Canada assigned to Connaught Laboratories Limited
BOVINE HERPESVIRUS TYPE 1 DELETION MUTANTS, VACCINES BASED THEREON, DIAGNOSTIC KITS FOR DETECTION OF BOVINE HERPESVIRUS TYPE 1
METHOD OF PRESERVATION OF VACCINES WITH POLYBIGUANIDE
A deletion mutant of bovine herpesvirus type 1 which has a deletion in the glycoprotein gE-gene and which may further have a deletion in the thymidine kinase gene and/or the glycoprotein gIgene, or have an insertion of a heterologous gene is disclosed. Recombinant nucleic acids which encode the gE-gene or a part thereof are also disclosed, in
A method for preventing or reducing bacterial contamination of a viral vaccine is disclosed. The method comprises adding an effective preserving amount of a polybiguanide-containing preservative composition to a solution containing vaccine virus or virus antigen. The method is particularly useful in preventing or reducing bacterial contamination of
6403363
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
process solutions involved in the manufacture of in¯uenza vaccines. Michelle Irene Gregarach Lawrence, Declan Greally, Great Britain assigned to Medeva Europe Limited 6406700 METHODS FOR PREPARATION OF VACCINES AGAINST CANCER The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit speci®c immune responses against cancer or preneoplastic cells, and to treat or prevent cancer. Pramod K. Srivastava, USA assigned to Fordham University 6406702 MULTIVALENT IN OVO AVIAN VACCINE A multivalent poultry vaccine is provided having two or more live biological agents or microbial components. Each live biological agent or microbial component is effective in preventing or treating an avian disease, and the multivalent vaccine is safe and effective for
287
immunizing poultry in ovo. Methods are also provided for vaccinating poultry by administering such a multivalent vaccine in ovo. Jagdev M. Sharma, USA assigned to Regents of the University of Minnesota 6410021 RECOMBINANT PARAINFLUENZA VIRUS VACCINES ATTENUATED BY DELETION OR ABLATION OF A NON-ESSENTIAL GENE A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of ribo¯avin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae. Troy E. Fuller, Martha H. Mulks, Bradley Thacker, USA. 6410023 RECOMBINANT MULTIVALENT VIRAL VACCINE Recombinant parain¯uenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid speci®ed by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby
288
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in viral growth characteristics, attenuation, plaque size, and/or a change in cytopathogenicity, among other novel phenotypes. A variety of additional mutations and nucleotide modi®cations are provided within the C, D and/or V ORF(s) deletion or ablation mutant PIV of the invention to yield desired phenotypic and structural effects.
invention also provides a method for immunizing chickens which comprises inoculating into growing egg a mixed vaccine comprising said composition plus another vaccine from at least one microorganisms selected from the group consisting of viruses other than virus of Marek's disease type 1, bacteria and protozoan.
Anna P. Durbin, Peter L. Collins, Brian R. Murphy, USA assigned to United States of America
The present invention is directed to identifying a gene, iroNec, from an extraintestinal isolate of E. coli, CP9. This gene was identi®ed from CP9 by screening a library of 527 mutant derivatives of CP9 with active TnphoA fusion in human urine. Two mutant derivative CP9.45 and CP9.82 possessed increased PhoA activity in urine due to the TnphoA insertion into iroNec. The product of this gene is an extracytoplasmic protein of 725 amino acids and can be used as vaccine against extraintestinal E. coli infections.
6410222 IN OVO VACCINATION OF MAREK'S DISEASE TYPE I VIRUS The preset invention provides a method for immunizing chickens which comprises inoculating into growing egg a composition comprising either cell-free attenuated viruses of Marek's disease type 1 or cells infected with attenuated viruses of Marek's disease type 1 capable of producing cell-free viruses. The present
Kenji Yokogawa, Masashi Sakaguchi, Eiji Tokunaga, Japan assigned to Juridical Foundation The Chemosero-Therapeutic Research Institute 6410703 IDENTIFICATION OF A VACCINE CANDIDATE FROM AN EXTRAINTESTINAL ISOLATE OF E. COLI
Thomas Russo, Ulrike Carlino, USA assigned to The Research Foundation of the State University of New York.
Comparative Immunology, Microbiology & Infectious Diseases 26 (2003) 285±288
PII: S 0147-957 1(02) 00069-3
285
www.elsevier.com/locate/cimid
286
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
6403094 CLOSTRIDIUM PERFRINGENS VACCINES The present invention provides proteins for use in vaccines which are capable of inducing protective antibodies directed against C. perfringens epsilon toxin when administered to animals or man and thereby providing prophylaxis or therapy against infection by C. perfringens epsilon toxin. Particularly the present invention provides proteins which are based upon the mature toxin of the clostridium perfringensepsilon toxin gene, but which have a mutation such that the amino acid at position 106 is different to the wild-type sequence and their use in vaccine compositions. Richard W. Titball, Ethel D. Williamson, Helen L. Havard, Petra C.F. Oyston, Dean W. Payne, Great Britain assigned to The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland. 6403097
addition to vaccines and a method of treatment. Franciscus Antonius Maria Rijsewijk, Johannes Theodorus van Oirschot, The Netherlands assigned to Stichting Centraal Diergeneeskundig Instituut 6403101 CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, speci®cally C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modi®cations are possible within the scope of this invention. Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn, Canada assigned to Connaught Laboratories Limited
BOVINE HERPESVIRUS TYPE 1 DELETION MUTANTS, VACCINES BASED THEREON, DIAGNOSTIC KITS FOR DETECTION OF BOVINE HERPESVIRUS TYPE 1
METHOD OF PRESERVATION OF VACCINES WITH POLYBIGUANIDE
A deletion mutant of bovine herpesvirus type 1 which has a deletion in the glycoprotein gE-gene and which may further have a deletion in the thymidine kinase gene and/or the glycoprotein gIgene, or have an insertion of a heterologous gene is disclosed. Recombinant nucleic acids which encode the gE-gene or a part thereof are also disclosed, in
A method for preventing or reducing bacterial contamination of a viral vaccine is disclosed. The method comprises adding an effective preserving amount of a polybiguanide-containing preservative composition to a solution containing vaccine virus or virus antigen. The method is particularly useful in preventing or reducing bacterial contamination of
6403363
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
process solutions involved in the manufacture of in¯uenza vaccines. Michelle Irene Gregarach Lawrence, Declan Greally, Great Britain assigned to Medeva Europe Limited 6406700 METHODS FOR PREPARATION OF VACCINES AGAINST CANCER The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit speci®c immune responses against cancer or preneoplastic cells, and to treat or prevent cancer. Pramod K. Srivastava, USA assigned to Fordham University 6406702 MULTIVALENT IN OVO AVIAN VACCINE A multivalent poultry vaccine is provided having two or more live biological agents or microbial components. Each live biological agent or microbial component is effective in preventing or treating an avian disease, and the multivalent vaccine is safe and effective for
287
immunizing poultry in ovo. Methods are also provided for vaccinating poultry by administering such a multivalent vaccine in ovo. Jagdev M. Sharma, USA assigned to Regents of the University of Minnesota 6410021 RECOMBINANT PARAINFLUENZA VIRUS VACCINES ATTENUATED BY DELETION OR ABLATION OF A NON-ESSENTIAL GENE A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of ribo¯avin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae. Troy E. Fuller, Martha H. Mulks, Bradley Thacker, USA. 6410023 RECOMBINANT MULTIVALENT VIRAL VACCINE Recombinant parain¯uenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid speci®ed by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby
288
Patents ALERT / Comp. Immun. Microbiol. Infect. Dis. 26 (2003) 285±288
partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in viral growth characteristics, attenuation, plaque size, and/or a change in cytopathogenicity, among other novel phenotypes. A variety of additional mutations and nucleotide modi®cations are provided within the C, D and/or V ORF(s) deletion or ablation mutant PIV of the invention to yield desired phenotypic and structural effects.
invention also provides a method for immunizing chickens which comprises inoculating into growing egg a mixed vaccine comprising said composition plus another vaccine from at least one microorganisms selected from the group consisting of viruses other than virus of Marek's disease type 1, bacteria and protozoan.
Anna P. Durbin, Peter L. Collins, Brian R. Murphy, USA assigned to United States of America
The present invention is directed to identifying a gene, iroNec, from an extraintestinal isolate of E. coli, CP9. This gene was identi®ed from CP9 by screening a library of 527 mutant derivatives of CP9 with active TnphoA fusion in human urine. Two mutant derivative CP9.45 and CP9.82 possessed increased PhoA activity in urine due to the TnphoA insertion into iroNec. The product of this gene is an extracytoplasmic protein of 725 amino acids and can be used as vaccine against extraintestinal E. coli infections.
6410222 IN OVO VACCINATION OF MAREK'S DISEASE TYPE I VIRUS The preset invention provides a method for immunizing chickens which comprises inoculating into growing egg a composition comprising either cell-free attenuated viruses of Marek's disease type 1 or cells infected with attenuated viruses of Marek's disease type 1 capable of producing cell-free viruses. The present
Kenji Yokogawa, Masashi Sakaguchi, Eiji Tokunaga, Japan assigned to Juridical Foundation The Chemosero-Therapeutic Research Institute 6410703 IDENTIFICATION OF A VACCINE CANDIDATE FROM AN EXTRAINTESTINAL ISOLATE OF E. COLI
Thomas Russo, Ulrike Carlino, USA assigned to The Research Foundation of the State University of New York.